𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Colchicine resistant friend cells: Application to the study of actinomycin D induced erythroid differentiation

✍ Scribed by Valerie Crichley; Dixie Mager; Alan Bernstein


Publisher
John Wiley and Sons
Year
1980
Tongue
English
Weight
620 KB
Volume
102
Category
Article
ISSN
0021-9541

No coin nor oath required. For personal study only.

✦ Synopsis


Abstract

Colchicine resistant (Cch^R^) mutants have been isolated from Friend erythroeleukemic cells by successive single‐step selections. Measurements of the rate of uptake of [^3^H]‐colchicine into whole cells, and the binding of [^3^H]‐colchicine to cytoplasmic extracts, suggest that these mutants are colchicine‐resistant due to a reduced membrane permeability to colchicine, rather than an altered intracellular colchicine‐binding target. Consistent with this conclusion is the observation that non‐toxic concentrations of Tween–80, a non‐ionic detergent, potentiated colchicine uptake into mutant cells. In addition, these Friend cell mutants, like Cch^R^ mutants of other cell types, are cross‐resistant to a variety of unrelated drugs, including daunomycin, puromycin, emetine, and actinomycin D.

A comparison of the dose‐response curves for the induction of Friend cell differentiation by actinomycin D of both wild‐type and two Cch^R^ cells suggests that actinomycin D permeation is required for its effects on Friend cell differentiation. Potentiation of actinomycin D uptake by Tween–80 significantly lowered the concentration of drug required to induce hemoglobin synthesis in the Cch^R^ cells, but had no significant effect on either actinomycin D induction of Cch^S^ cells or DMSO induction of both Cch^S^ and Cch^R^ cells. In common with other chemical inducers of Friend cell differentiation, the addition of actinomycin D results in an early decrease in ^86^ RbCl uptake, although this effect on transport occurred 14 hours later than that observed with DMSO.


📜 SIMILAR VOLUMES


Resistance to 1,25D-induced differentiat
✍ Edward Garay; Robert Donnelly; Xuening Wang; George P. Studzinski 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 438 KB

## Abstract The anti‐neoplastic effects of 1,25‐dihydroxyvitamin D~3~ (1,25D) are well documented in numerous tumor cell systems and animal models of cancer. However, despite this pre‐clinical success, the clinical use of 1,25D is currently impeded by the dose‐limiting hypercalcemia, and the risk o